Jobs / United States / Glaxosmithkline LLC
Director, Clinical Operations Asset Lead
Glaxosmithkline LLC · 🇺🇸 10 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Position Summary The Clinical Operations Asset Lead is the single point of accountability for clinical operations delivery across the full asset lifecycle. Representing Global Clinical Operations at the asset level, the COAL sets and delivers the program‑level operational strategy that enables execution of the scientific vision. Working in close partnership with clinical, biostatistics, and functional experts, the COAL drives informed decision‑making, provides strategic leadership to Study Delivery Teams, and ensures high‑quality, on‑time delivery—while retaining full accountability for overall asset outcomes. This COAL may take on responsibilities across both early and late phase, depending upon demand in our RIIRU portfolio. Key Responsibilities: Asset & Development Strategy • Contribute to the Clinical Development Plan (CDP) and Integrated Evidence Plan (IEP) across Research, Development, and LCM • Ensure study designs are operationally feasible, regionally compliant, cost‑effective, and deliver high‑quality data • Provide protocol‑level operational input and support amendments through governance review Resourcing & Vendor Strategy • Lead and own the asset‑level resourcing strategy (in‑house vs outsourced) • Approve vendor selection, contracting, and oversight in line with GSK standards Delivery Quality & Inspection Readiness • Serve as escalation point for critical operational, quality, and GCP issues • Lead cross‑functional coordination to ensure inspection readiness and high‑quality study delivery • Ensure transparent communication of risks, issues, and successes across GCO Operational Delivery & Governance • Own asset‑level delivery plans, scenario modeling, and budget forecasts • Drive innovative, patient‑centric and efficient approaches to study execution • Represent Clinical Operations at governance boards and support clinical filing activities Risk, Data & Stakeholder Management • Own the asset‑level risk register and mitigation strategy using Quality by Design • Ensure accurate, current operational data in GSK systems until transition to study teams • Lead internal and external stakeholder engagement across the asset Capabilities: • Demonstrates conceptual, analytical and strategic thinking to innovative approaches to clinical delivery, leverage external technology and networks and build internal capability • Ability to translate strategic concepts, scientific requirements, stakeholder feedback and expectations into cohesive actions for the Asset team • Innovative and change adept whilst identifying and embracing risks as opportunities • Ability to establish and build internal and external relationships at all levels in a highly dynamic and matrixed environment, demonstrating conflict management and negotiation skills • Partnering skills with key role such as clinical science, biostatistics and other subject matter experts (SME) at asset level to articulate and champion key decisions and strategy • Excellent leadership skills building and managing matrixed teams, promoting motivation and empowerment of others to accomplish individual,